CONTEXT: Little direct evidence exists on the relative efficacies of different smoking cessation pharmacotherapies, yet such evidence is needed to make informed decisions about their clinical use. OBJECTIVE: To assess the relative efficacies of 5 smoking cessation pharmacotherapy interventions using placebo-controlled, head-to-head comparisons. DESIGN: A randomized, double-blind, placebo-controlled clinical trial. SETTING: Two urban research sites. PATIENTS: One thousand five hundred four adults who smoked at least 10 cigarettes per day during the past 6 months and reported being motivated to quit smoking. Participants were excluded if they reported using any form of tobacco other than cigarettes; current use of bupropion; having a current psychosis or schizophrenia diagnosis; or having medical contraindications for any of the study medications. INTERVENTIONS: Participants were randomized to 1 of 6 treatment conditions: nicotine lozenge, nicotine patch, sustained-release bupropion, nicotine patch plus nicotine lozenge, bupropion plus nicotine lozenge, or placebo. In addition, all participants received 6 individual counseling sessions. MAIN OUTCOME MEASURES: Biochemically confirmed 7-day point-prevalence abstinence assessed at 1 week after the quit date (postquit), end of treatment (8 weeks postquit), and 6 months postquit. Other outcomes were initial cessation, number of days to lapse, number of days to relapse, and latency to relapse after the first lapse. RESULTS: All pharmacotherapies differed from placebo when examined without protection for multiple comparisons (odds ratios, 1.63-2.34). With such protection, only the nicotine patch plus nicotine lozenge (odds ratio, 2.34, P < .001) produced significantly higher abstinence rates at 6-month postquit than did placebo. CONCLUSION: While the nicotine lozenge, bupropion, and bupropion plus lozenge produced effects that were comparable with those reported in previous research, the nicotine patch plus lozenge produced the greatest benefit relative to placebo for smoking cessation.
RCT Entities:
CONTEXT: Little direct evidence exists on the relative efficacies of different smoking cessation pharmacotherapies, yet such evidence is needed to make informed decisions about their clinical use. OBJECTIVE: To assess the relative efficacies of 5 smoking cessation pharmacotherapy interventions using placebo-controlled, head-to-head comparisons. DESIGN: A randomized, double-blind, placebo-controlled clinical trial. SETTING: Two urban research sites. PATIENTS: One thousand five hundred four adults who smoked at least 10 cigarettes per day during the past 6 months and reported being motivated to quit smoking. Participants were excluded if they reported using any form of tobacco other than cigarettes; current use of bupropion; having a current psychosis or schizophrenia diagnosis; or having medical contraindications for any of the study medications. INTERVENTIONS:Participants were randomized to 1 of 6 treatment conditions: nicotine lozenge, nicotine patch, sustained-release bupropion, nicotine patch plus nicotine lozenge, bupropion plus nicotine lozenge, or placebo. In addition, all participants received 6 individual counseling sessions. MAIN OUTCOME MEASURES: Biochemically confirmed 7-day point-prevalence abstinence assessed at 1 week after the quit date (postquit), end of treatment (8 weeks postquit), and 6 months postquit. Other outcomes were initial cessation, number of days to lapse, number of days to relapse, and latency to relapse after the first lapse. RESULTS: All pharmacotherapies differed from placebo when examined without protection for multiple comparisons (odds ratios, 1.63-2.34). With such protection, only the nicotine patch plus nicotine lozenge (odds ratio, 2.34, P < .001) produced significantly higher abstinence rates at 6-month postquit than did placebo. CONCLUSION: While the nicotine lozenge, bupropion, and bupropion plus lozenge produced effects that were comparable with those reported in previous research, the nicotine patch plus lozenge produced the greatest benefit relative to placebo for smoking cessation.
Authors: Tai-Hing Lam; Abu Saleh M Abdullah; Sophia S C Chan; Anthony J Hedley Journal: Psychopharmacology (Berl) Date: 2004-07-29 Impact factor: 4.530
Authors: Saul Shiffman; Deborah M Scharf; William G Shadel; Chad J Gwaltney; Qianyu Dang; Stephanie M Paton; Duncan B Clark Journal: J Consult Clin Psychol Date: 2006-04
Authors: M E Mooney; V I Reus; J Gorecki; S M Hall; G L Humfleet; R F Muñoz; K Delucchi Journal: Clin Pharmacol Ther Date: 2007-08-08 Impact factor: 6.875
Authors: Serena Tonstad; Philip Tønnesen; Peter Hajek; Kathryn E Williams; Clare B Billing; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Timothy B Baker; Robin Mermelstein; Linda M Collins; Megan E Piper; Douglas E Jorenby; Stevens S Smith; Bruce A Christiansen; Tanya R Schlam; Jessica W Cook; Michael C Fiore Journal: Ann Behav Med Date: 2011-04
Authors: Carol Mitchell; Megan E Piper; Claudia E Korcarz; Kristin Hansen; JoAnne Weber; Michael C Fiore; Timothy B Baker; James H Stein Journal: J Diagn Med Sonogr Date: 2017-12-19
Authors: Tanya R Schlam; Timothy B Baker; Stevens S Smith; Jessica W Cook; Megan E Piper Journal: Nicotine Tob Res Date: 2020-01-27 Impact factor: 4.244
Authors: Stevens S Smith; Danielle E McCarthy; Sandra J Japuntich; Bruce Christiansen; Megan E Piper; Douglas E Jorenby; David L Fraser; Michael C Fiore; Timothy B Baker; Thomas C Jackson Journal: Arch Intern Med Date: 2009-12-14